Actions

The flow cytometric diagnosis of AML: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
 
(271 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Acute leukaemia types]]
 
----
----
<div style="width: 200px">
{| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px silver;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy"
| colspan="1"''|[[Flow Cytometry|Return to previous page]]''
|}
</div>


<div style="width: 95%">
--------
 
<div style="width: 100%">
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
|colspan="1" style = "font-size:90%; color:black; background:#ddeee1"|'''1.''' '''The immunophenotype of AML blasts will (generally) reflect their primitive nature'''
|colspan="1" style = "font-size:90%; color:black; background: #bcd4e6"|'''1. The immunophenotype of the blast cells should be consistent with their "primitive" nature'''
|}
|}
 
</div>
 


[[Image:AML M1.png|110px]]
[[Image:AML M1.png|110px]]
<span style="font-size:90%;"></br>''The typical "primitive" morphology of blast cells is generally accompanied by signs of primitive immunophenotype''</span>
</br></br><span style="font-size:90%;">Assigning primitive nature in most cases is straightforward, but some types of AML may present difficulties.</span>


*Most often in AML typical features of immature cells will be found with: weak expression of '''CD45''', together with expression of '''CD34''' and/or '''CD117'''. Other markers may be useful in difficult cases (see [[Markers used to demonstrate primitive nature in AML|Click for more detailed description]])
<div style="width: 95%; font-size:90%;">
*However in cases where blast cells show more differentiation their nature may be less clear. This is most frequently encountered in monocytic cases of AML or in APL ([[Atypical patterns of primitive marker expression in acute myeloid leukaemia|Click for a more detailed description]])
{| class="wikitable" style="border-style: solid; border-width: 4px; color:black"
!colspan="1" style = "background:#ddeee1; border:solid; border-width: 3px;"|<span style="font-size:90%;">'''Demonstrating primitive phenotype in AML'''</span></br>
|-
!colspan="1" style = "background:white; border:solid; border-width: 1px; color:black"|In most cases, cells of AML will demonstrate typical features of immature cells with: '''weak expression of CD45''', and expression of '''CD34''' and/or '''CD117'''</br>However, patterns are not always typical and difficult cases other markers of early differentiation may also help</br></br>[[Markers used to demonstrate primitive nature in AML|''Click for a more detailed table of markers associated with primitive phenotype'']]
|-
!colspan="1" style = "background:#ddeee1;border:solid"|<span style="font-size:90%;">'''Difficulties may occur where blast cells have significant maturation so their primitive nature may be less easy to demonstrate.'''</span></br>
|-
!colspan="1" style = "background:white; border:solid; border-width: 1px;"|Difficulties are most frequently encountered in monocytic cases of AML, or in acute promyelocytic leukaemia (APL) (although occasionally in other types).</br></br>[[Atypical patterns of primitive marker expression in acute myeloid leukaemia|Click to see common patterns that may cause difficulty in assigning primitive phenotype]]
|-
|}
</div>




----
----


<div style="width: 95%">
<div style="width: 100%">
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
|colspan="1" style = "font-size:90%; color:black; background:#ddeee1"|'''2. The cases should express sufficient markers to allow myeloid lineage to be assigned'''
|colspan="1" style = "font-size:90%; color:black; background:#bcd4e6"|'''2. The immunophenotype of the blast cells should allow myeloid lineage to be assigned'''
|}
|}


[[Image:AML M2.png|130px]]   
[[Image:AML M2.png|130px]]   
<span style="font-size:90%;"></br>''Like Auer rods or granulation in morphology, particular immunophenotypic features support assignment to myeloid lineage''</span>




The requirements to diagnose AML by flow cytometry have been established by WHO, cases should meet either of two alternaitive criteria (most will meet both):
<span style="font-size:90%;">The criteria to assign myeloid lineage in AML have been established, alternative sets of diagnostic criteria may be used (although many cases will meet more than one criteria set):


<div style="width: 95%"; >
<div style="width: 95%; font-size:90%;">
{| class="wikitable"  
{| class="wikitable" style="border-style: solid; border-width: 4px; color:black"
!colspan="1" style = "background:palegrey;border:solid"|'''Criteria Set 1:'''</br>
!colspan="1" style = "background:#ddeee1; border:solid; border-width: 3px;"|<span style="font-size:90%;">'''Pattern A: AML - diagnosis based on lineage-defining markers'''</span></br>
|-
|-
!colspan="1" style = "background:white; font-size:90%; border:solid; "|A myeloid '''lineage-defining''' marker pattern is present '''and''' no lineage-defining markers of T or B cells are present</br>([[Immnophenotypic markers in AML|'''Click for detaied description''']])
!colspan="1" style = "background:white; border:solid; border-width: 1px; color:black"|A myeloid lineage-defining marker pattern is present '''and''' no lineage-defining markers of T or B cells are present</br></br>
<span style="font-size:100%;">[[Flow cytometry: Myeloid-defining markers|Click to view table of criteria]]</span>
|-
|-
!colspan="1" style = "background:palegrey;border:solid"|'''Criteria Set 2:'''</br>
!colspan="1" style = "background:#ddeee1;border:solid"|<span style="font-size:90%;">'''Pattern B: AML - diagnosis based on myeloid-lineage-associated marker patterns'''</span></br>
|-
|-
!colspan="1" style = "background:white;border:solid; font-size:90%;"|At least '''two myeloid lineage-associated''' markers are present '''and''' there are no lineage defining markers of T or B cells '''and''' no more than one: T-cell '''or''' B-cell lineage-associated markers are  present</br>([[Immnophenotypic markers in AML|'''Click for detaied description''']])
!colspan="1" style = "background:white; border:solid; border-width: 1px;"|At least two myeloid lineage-associated markers are present '''and''' there are no lineage defining markers of T or B cells '''and''' no more than one T-cell or B-cell lineage-associated marker is present</br></br>
<span style="font-size:90%;">[[Myeloid lineage-associated markers|Click to view table of criteria]]</span>
|-
!colspan="1" style = "background:#ddeee1;border:solid"|<span style="font-size:90%;">'''Pattern C: AML - diagnosis based on less frequent differentiation patterns'''</span></br>
|-
!colspan="1" style = "background:white; border:solid; border-width: 1px;"|In those rarer cases of erythroid or megakaryocytic differentiation, full myeloid criteria may not be met requiring these patterns to be specifically diagnosed.</br></br>
<span style="font-size:90%;">[[Marker patterns erythroid or megakaryocyte differentiation|Click to view table of criteria]]</span>
|}
|}
 
</div>
 
'''NOTE''' In cases with atypical maturation an extended marker panel may be used to allow the differentiationto pattern be identified (e.g. erythroid or megakarocytic). These markers may also be used in difficult cases to provide additional evidence of myeloid lineage. However the specificity of these markers is often less than the general myeloid-associated markers so care is required when using them in this way. </br>
 
[[Additional immunophenotypic markers useful in lineage assignment or subtyping of AML|Click for table of extended marker set for AML immunophenotype]]




----
----


<div style="width: 95%">
<div style="width: 100%">
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black"
|colspan="1" style = "font-size:90%; color:black; background:#ddeee1"|'''3. Are atypical features present? Should alternative diagnoses be considered?'''
|colspan="1" style = "font-size:90%; color:black; background:#bcd4e6"|'''3. Alternative diagnoses in difficult cases'''
|}
|}
[[Image:AML M1.png|110px]]
[[Image:Lymphoblast.png|110px]]
<span style="font-size:90%;"></br>''Difficult cases often arise where lineage may be unclear. Either because myeloid lineage cannot be confidently assigned or because markers of other lineage are present - in such cases it is important to consider possible alternative diagnoses''</span>
</div>
*The expression of "non-lineage" markers in AML is well recognised, and in many cases these should be simply regarded as "expected aberrancy" while others are associated with specific AML subtypes, these do not necessarily indicate mixed phenotype, but when these markers are detected then this requires specific consideration ([[Table of frequent aberrant markers in AML|Click here for further detail]])
<span style="font-size:90%;"></br>In some cases myeloid markers may be present but full lineage may be unclear - in such cases it is important to consider possible alternative diagnoses</span></br>
*Some features should give concern for mixed phenotype or alternative diagnosis. While these circumstances are infrequent, it is important that where immunophenotype is atypical then the criteria should be carefully reviewed ('''see the table below more detailed guidance''').


----


Possible alternative diagnoses in difficult cases:
<span style="font-size:90%;">Alternative potential diagnoses in difficult cases with myeloid marker expression:</span>


<div style="width: 95%"; font-size:95%>
<div style="width: 95%; font-size:90%;">
{| class="wikitable"  
{| class="wikitable" style="border-style: solid; border-width: 4px; color:black"
!colspan="2" style = "background:palegrey;border:solid"|'''1.''' Mixed Phenotype Acute Leukaemia.  See: '''[[MPAL]]'''
!colspan="2" style = "background:#ddeee1;border:solid"|<span style="font-size:90%;">'''Mixed Phenotype Acute Leukaemia''' (MPAL)</span>
|-
|-
!colspan="2" style = "background:white;border:solid; font-size:90%;"| Consider MPAL if: you are able to assign myeloid lineage '''but''' the cells also express either a lineage-defining marker of T or B cells, or more than one lineage associated marker of T or B cells.</br></br>
!colspan="2" style = "background:white;border:solid;"|Consider where myeloid lineage can be assigned based on '''lineage-specific''' patterns '''but''' the cells also have marker patterns that meet the criteria to assign T or B cell lineage.</br></br>[[Flow cytometry:MPAL|''Click for diagnostic criteria of MPAL'']]
|-
|-
!colspan="2" style = "background:palegrey;border:solid"| '''2.''' Acute Undifferentiated Leukaenmia or Acute Leukaemia not otherwise sepcified: See '''[[AUL]]'''
!colspan="2" style = "background:#ddeee1;border:solid;"|'''Acute Undifferentiated Leukaemia''' (AUL)
|-
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"| Consider AUL or AL-NOS if: There is insufficient evidence to assign myeloid lineage, '''and''' you cannot assign T-cell or B-cell lineage ''''OR''' significant uncertainty remains while other tests are awaited</br></br>
!colspan="2" style = "background:white; border:solid;"|'''Consider AUL:''' In cases where the evidence is insufficient to assign myeloid lineage '''and''' there is insufficient evidence to assign to T-cell or B-cell lineage </br></br>[[Flow cytometry:AUL|''Click for diagnostic criteria of AUL'']]
|-
|-
!colspan="2" style = "background:palegrey;border:solid"| '''3''' Non-haematological malignancy: See '''[[Non-haematological malignancy]]'''
!colspan="2" style = "background:#ddeee1;border:solid"|'''Acute Leukaemia of ambiguous lineage not otherwise sepcified''' (ALAL-NOS)
|-
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"| Consider non-haematological malignancy if: myeloid markers may be expressed but not conclusice, CD45 expression is very weak, and the presentation is atypical.</br></br>
!colspan="2" style = "background:white; border:solid;"|'''Consider ALAL-NOS:''' if classification to specific lineage is not possible '''but''' blast cells cannot be classed as AUL or MPAL.</br></br>[[Flow cytometry:ALAL-NOS|''This is most often a useful provisional diagnosis - click here for details'']]</br>
|-
|-
!colspan="2" style = "background:lightgrey;border:solid"|'''4.''' Early T-cell precursor ALL: See: '''[[ETP-ALL]]'''
!colspan="2" style = "background:#ddeee1;border:solid"|''' Early T-cell precursor acute lymphoblastic leukaemia''' (ETP-ALL)
|-
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"| The marker pattern is of a primitive T cell neoplasm with lineage-defining criteria, but there are also myeloid markers expressed</br></br>
!colspan="2" style = "background:white; border:solid;"| This disorder has diagnostic criteria sufficient to assign T cell lineage (cCD3 is expressed) but may express myeloid-associated antigens cases may share features with MPAL M/T</br></br>[[Flow cytometry:ETP-ALL|''Click for diagnostic criteria of ETP-ALL'']]
|-
|-
!colspan="2" style = "background:lightgrey;border:solid"|'''5.''' Blastic plasmacytoid dendritic cell neoplasm: See: '''[[BPDCN]]'''
!colspan="2" style = "background:#ddeee1;border:solid"|'''Blastic plasmacytoid dendritic cell neoplasm''' (BPDCN)
|-
|-
!colspan="2" style = "background:white; border:solid; font-size:90%;"| Morphologically BPDCN may resemble AML (particularly monocytic), frequently with skin accompanying rash. Identification may require additional markers</br></br>
!colspan="2" style = "background:white; border:solid;"|'''Consider BPDCN:''' Generally in cases that resemble AUL (rarely AML), most often with skin rash. A specific marker profile should be sought: expression of bright CD4 and/or CD56 is expected. CD33 is frequently expressed but other myeloid markers are less frequent and MPO and CD34 should be absent. Look for specific additional markers as described in the diagnostic criteria.</br></br>[[Flow cytometry:BPDCN|''Click for diagnostic criteria of BPDCN'']]
|}
|}
</br></br><span style="font-size:90%;">'''FINAL NOTE''' Some "non-lineage" markers are frequently expressed in AML and may be associated with specific AML subtypes ([[Table of frequent aberrant markers in AML|Click here for further detail]]). Other features should give concern for alternative diagnosis (see the table below more detailed guidance).
----
----

Latest revision as of 15:28, 15 March 2024



1. The immunophenotype of the blast cells should be consistent with their "primitive" nature

AML M1.png

Assigning primitive nature in most cases is straightforward, but some types of AML may present difficulties.

Demonstrating primitive phenotype in AML
In most cases, cells of AML will demonstrate typical features of immature cells with: weak expression of CD45, and expression of CD34 and/or CD117
However, patterns are not always typical and difficult cases other markers of early differentiation may also help

Click for a more detailed table of markers associated with primitive phenotype
Difficulties may occur where blast cells have significant maturation so their primitive nature may be less easy to demonstrate.
Difficulties are most frequently encountered in monocytic cases of AML, or in acute promyelocytic leukaemia (APL) (although occasionally in other types).

Click to see common patterns that may cause difficulty in assigning primitive phenotype



2. The immunophenotype of the blast cells should allow myeloid lineage to be assigned

AML M2.png


The criteria to assign myeloid lineage in AML have been established, alternative sets of diagnostic criteria may be used (although many cases will meet more than one criteria set):

Pattern A: AML - diagnosis based on lineage-defining markers
A myeloid lineage-defining marker pattern is present and no lineage-defining markers of T or B cells are present

Click to view table of criteria

Pattern B: AML - diagnosis based on myeloid-lineage-associated marker patterns
At least two myeloid lineage-associated markers are present and there are no lineage defining markers of T or B cells and no more than one T-cell or B-cell lineage-associated marker is present

Click to view table of criteria

Pattern C: AML - diagnosis based on less frequent differentiation patterns
In those rarer cases of erythroid or megakaryocytic differentiation, full myeloid criteria may not be met requiring these patterns to be specifically diagnosed.

Click to view table of criteria



3. Alternative diagnoses in difficult cases

Lymphoblast.png


In some cases myeloid markers may be present but full lineage may be unclear - in such cases it is important to consider possible alternative diagnoses


Alternative potential diagnoses in difficult cases with myeloid marker expression:

Mixed Phenotype Acute Leukaemia (MPAL)
Consider where myeloid lineage can be assigned based on lineage-specific patterns but the cells also have marker patterns that meet the criteria to assign T or B cell lineage.

Click for diagnostic criteria of MPAL
Acute Undifferentiated Leukaemia (AUL)
Consider AUL: In cases where the evidence is insufficient to assign myeloid lineage and there is insufficient evidence to assign to T-cell or B-cell lineage

Click for diagnostic criteria of AUL
Acute Leukaemia of ambiguous lineage not otherwise sepcified (ALAL-NOS)
Consider ALAL-NOS: if classification to specific lineage is not possible but blast cells cannot be classed as AUL or MPAL.

This is most often a useful provisional diagnosis - click here for details
Early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL)
This disorder has diagnostic criteria sufficient to assign T cell lineage (cCD3 is expressed) but may express myeloid-associated antigens cases may share features with MPAL M/T

Click for diagnostic criteria of ETP-ALL
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Consider BPDCN: Generally in cases that resemble AUL (rarely AML), most often with skin rash. A specific marker profile should be sought: expression of bright CD4 and/or CD56 is expected. CD33 is frequently expressed but other myeloid markers are less frequent and MPO and CD34 should be absent. Look for specific additional markers as described in the diagnostic criteria.

Click for diagnostic criteria of BPDCN



FINAL NOTE Some "non-lineage" markers are frequently expressed in AML and may be associated with specific AML subtypes (Click here for further detail). Other features should give concern for alternative diagnosis (see the table below more detailed guidance).